Brokerages Set Zenas BioPharma, Inc. (NASDAQ:ZBIO) PT at $43.14

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has earned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $43.1429.

A number of equities analysts have commented on ZBIO shares. Wedbush reissued an “outperform” rating and set a $45.00 target price on shares of Zenas BioPharma in a report on Monday, December 22nd. Evercore assumed coverage on Zenas BioPharma in a research report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $44.00 price objective on shares of Zenas BioPharma in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $48.00 target price on shares of Zenas BioPharma in a research report on Tuesday, January 6th.

Zenas BioPharma Stock Down 2.2%

ZBIO opened at $25.26 on Friday. The company has a market cap of $1.36 billion, a PE ratio of -3.57 and a beta of -1.94. Zenas BioPharma has a twelve month low of $6.11 and a twelve month high of $44.60. The company has a 50-day moving average price of $23.96 and a 200 day moving average price of $26.58. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37.

Insiders Place Their Bets

In related news, Director Patricia L. Allen acquired 15,700 shares of Zenas BioPharma stock in a transaction that occurred on Thursday, February 12th. The shares were purchased at an average price of $24.85 per share, for a total transaction of $390,145.00. Following the completion of the transaction, the director owned 15,700 shares in the company, valued at $390,145. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Hongbo Lu acquired 25,985 shares of the stock in a transaction on Wednesday, February 11th. The shares were bought at an average cost of $22.50 per share, for a total transaction of $584,662.50. Following the purchase, the director directly owned 347,968 shares of the company’s stock, valued at $7,829,280. The trade was a 8.07% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 202,845 shares of company stock valued at $3,747,185 in the last ninety days. 16.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ZBIO. PNC Financial Services Group Inc. grew its holdings in shares of Zenas BioPharma by 41.2% in the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock valued at $89,000 after purchasing an additional 2,679 shares during the period. Geode Capital Management LLC grew its stake in shares of Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after buying an additional 16,461 shares during the period. Intech Investment Management LLC increased its holdings in shares of Zenas BioPharma by 13.9% during the 2nd quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock worth $128,000 after buying an additional 1,607 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after buying an additional 8,207 shares during the last quarter. Finally, Federated Hermes Inc. raised its position in shares of Zenas BioPharma by 60.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after buying an additional 703,838 shares during the period.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.